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Background: In patients hospitalized over a 4 year period for pulmonary embolism (PE), we assessed relationships
of testosterone (TT) and estrogen therapy (ET) anteceding PE in patients found to have familial-acquired thrombophilia.
Methods: From 2011 through 2014, 347 patients were hospitalized in Cincinnati Mercy Hospitals with PE.
Retrospective chart review was used to identify patients receiving TT or ET before PE; coagulation studies were
done prospectively if necessary.
Results: Preceding hospitalization for PE, 8 of 154 men (5 %) used TT, and 24 of 193 women (12 %) used ET.
The median number of months from the initiation of TT or ET to development of PE was 7 months in men and
18 months in women. Of the 6 men having coagulation measures, all had ≥ 1 thrombophilia, and of the 18 women
having measures of coagulation, 16 had ≥ 1 thrombophilia. The sensitivity of a previous history of thrombosis to
predict PE was low, 25 % (2/8 men), 4 % (1/24 women).
Conclusions: Of 154 men hospitalized for PE, 8 (5 %) used TT, and of 193 women, 24 (12 %) used ET. Our data
suggests that PE is an important complication of TT in men and ET in women, in part reflecting an interaction
between familial and acquired thrombophilia and exogenous hormone use.
Keywords: Thrombophilia, Testosterone, Estrogen, Pulmonary embolusBackground
When testosterone therapy (TT) is given to men or
women with underlying familial or acquired thrombo-
philia, venous thromboembolism (VTE), deep venous
thrombosis (DVT), pulmonary emboli (PE), ocular throm-
bosis, and osteonecrosis may occur [1–8]. In 67 recently
reported cases of VTE, Glueck et al. [8] compared
thrombophilia in 67 cases (59 men and 8 women) with
thrombotic events after starting testosterone therapy
versus 111 patient controls having unprovoked venous
thrombotic events without TT. In the 67 patients,* Correspondence: Marloe.prince@gmail.com
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embolism, 16 osteonecrosis, and 4 ocular thrombosis)
occurred 6 months (median) after starting TT. Cases
differed from controls for factor V Leiden heterozygosity
(16 of the 67 [24 %] vs 13 [12 %] of the 111, P = .038) and
for lupus anticoagulant (9 [14 %] of the 64 vs 4 [4 %] of
the 106, P = .019). After a first thrombotic event and
continuing TT, 11 cases had a second thrombotic
event, despite adequate anticoagulation, 6 of whom, still
anticoagulated, had a third thrombosis. Screening for
thrombophilia before starting TT should identify men
and women at high risk for thrombotic events with an
adverse risk-benefit ratio for TT. Glueck et al. [8] con-
cluded that when TT is given to patients with familial
and acquired thrombophilia, thrombosis may occur and
recur in thrombophilic men despite anticoagulation.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Percent of 154 men admitted with pulmonary embolism (PE)
who used testosterone therapy before PE, and the percent who
had cancer associated with PE. Percent of 193 women admitted
with pulmonary embolism (PE) who used estrogen-progestin birth
control pills (n = 16), estrogen-progestin hormone replacement
therapy (n = 6) or progesterone (n = 2) before PE, and percent
who had cancer associated with PE
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velop severe post thrombotic syndrome within 5 years
[9]. Despite adequate treatment, up to 25 % of patients
with symptomatic DVT-PE have recurrent VTE within 5
years [10]. Moreover, 25 % of patients with VTE do not
survive the first year after diagnosis [11].
In 596 men hospitalized for DVT-PE, we previously
reported that 7 (1.2 %) had taken TT before and at time
of their admission [3]. Of these 7 men, all 5 who had
evaluation of thrombophilia-hypofibrinolysis were found
to have previously undiagnosed procoagulants. Separ-
ately, we studied 147 men hospitalized for DVT-PE,
finding 2 (1.4 %) with antecedent TT use [5]. Both men
had previously undiagnosed thrombophilia [5]. Parallel
to the TT-VTE relationship in men, estrogen-progestin
birth control pills (BCP) and hormone replacement ther-
apy (HRT) in women are associated with VTE [12–14],
and the issue of screening for thrombophilia before pre-
scription of BCP or HRT is contentious because of cost-
effectiveness issues [15].
In 347 patients (154 men, 193 women) hospitalized
over a 4-year period for pulmonary embolism, we in-
vestigated testosterone and estrogen therapy (ET) use





The study was carried out following a protocol approved
by the Jewish Hospital Institutional Review Board, with
signed informed consent. No identifiable clinical data is
presented.
From 2011 through 2014, using review of electronic
medical records, 347 patients were hospitalized in
Cincinnati Mercy Hospitals with PE. Only patients
hospitalized for PE were studied. Retrospective chart
review was used to document TT or ET use anteced-
ing PE. We prospectively performed coagulation stud-
ies in those patients who used TT or ET, not having
previous evaluation of thrombophilia-hypofibrinolysis.
Retrospectively, we reviewed coagulation data obtained
at hospitalization for PE from electronic medical records
in two other groups of patients not exposed to TT or
ET, 78 with cancer associated with PE (17 had coagula-
tion data), and 237 free of cancer (116 had coagulation
data).
Studies of thrombophilia and hypofibrinolysis
PCR measures of the Factor V Leiden, prothrombin,
MTHFR mutations and serologic measures of activated
protein C resistance [16, 17], antigenic proteins anti-
thrombin III, C, total S, free S, homocysteine, factors
VIII and XI [18, 19], the lupus anticoagulant, andanticardiolipin antibodies were carried out using estab-
lished methods [20–22].
PCR measures of the 4G/5G mutation in the plas-
minogen activator inhibitor (Serpine1) gene [8, 23–25]
were carried out using established methods [20–22].
Serologic studies of plasminogen activator inhibitor ac-
tivity were not done.Statistical methods
Within gender, users and non-users of ET/TT were
compared by Fisher’s exact test and by Wilcoxon tests.
Thrombophilia in the 24 hormone users (6 men on TT,
18 women on ET) was compared to 116 cases (62 men,
54 women) with PE, not receiving TT or ET and free of
cancer, and to 17 cases (9 men, 8 women) with cancer,
not receiving TT or ET by Fisher’s exact test.
Results
Preceding hospitalization for PE, of the 154 men and
193 women, 8 men (5 % of men) used TT, 24 women
(12 % of women) used ET (16 estrogen-progestin birth
control pills [BCP], 6 hormone replacement therapy
[HRT], 2 progesterone), Fig. 1, Table 1. From the initi-
ation of TT or ET to development of PE, the median
time was 7 months in men and 18 months in women.
Median age in the 8 men was 56, marginally (p = .068)
younger than in the 146 men not on TT (65). Median
age in the 24 women with PE on ET was 38, younger
than 169 women not taking ET (69, p < .0001), Table 1.
Women taking ET with subsequent PE were less likely
Table 1 Demographics in 347 pulmonary embolism patients (193 women, 154 men), by gender and by hormone use
Women
Hormone user, n = 24 (12 %) Non user, n = 169 (88 %) all women n = 193 (100 %)
Age (year) 42 ± 13, median 38**** 66 ± 17, median 69 63 ± 18, median 65
Smoking 7/24 (29 %)* 96/169 (57 %) 103/193 (53 %)
Hormone BC pill 16 (67 %) Estrogen 6 (25 %) Progesterone 2 (8 %)
Cancer 0/24 (0 %)** 45/169 (27 %) 45/193 (23 %)
DM 2/24 (8 %) 42/169 (25 %) 44/193 (23 %)
Death 0/24 (0 %) 3/169 (2 %) 3/193 (2 %)
Thrombosis history 1/24 (4 %)* 40/168 (24 %), 1 missing 41/193 (21 %)
Men
Hormone user, n = 8 (5 %) Non user n = 146 (95 %) All men n = 154 (100 %)
Age (year) 48 ± 23, median 56 63 ± 17, median 65 62 ± 17, median 64
Smoking 5/8 (63 %) 103/146 (71 %) 108/154 (70 %)
Hormone Testosterone
Cancer 0/8 (0 %) 33/146 (23 %) 33/154 (21 %)
DM 2/8 (25 %) 31/146 (21 %) 33/154 (21 %)
Death 0/8 (0 %) 2/146 (1 %) 2/154 (1 %)
Thrombosis history 2/8 (25 %) 31/146 (21 %) 33/154 (21 %)
* p < .05, ** p < .01, comparing hormone user vs non user in each gender by Fisher’s exact test
**** p < .0001, comparing hormone user vs non user in each gender by Wilcoxon test
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likely to have a previous thrombosis history (4 % vs 24
%, p < .05), Table 1.
Of the 8 men using TT before their PE, 6 used TT
gels, 50 mg/day, and 2 had intra muscular TT 50 mg/
week. Of these 8 men, 5 (63 %) smoked, 2 had a previ-
ous history of thrombotic events, and 2 had type 2 dia-
betes, Table 1.
Coagulation evaluations were done in 6 of the 8 men
with TT anteceding PE, Table 2. All 6 had ≥ 1 throm-
bophilia or hypofibrinolysis: 1 heterozygous for the
G20210A prothrombin gene mutation, 1 homozygousTable 2 Abnormal measures of thrombophilia and hypofibrinolysis
embolism (6 men had coagulation measures)
PTG MTHFR PAIG Homocysteine







adated cut point for Homocysteine high: ≥ 15 (11/15/08-12/2/14); ≥ 10.4 (after 12/3/
bdated cut point for IgG high: ≥ 23 GPL (before 10/31/12); ≥ 15 (after 11/1/12)for the 4G4G PAI-1 gene mutation, 1 with high factor
VIII, 1 with high ACLA IgG, 3 with high homocysteine
(1 of whom had MTHFR C677T homozygosity), 2 with
low protein C, 2 with low protein S, and 2 with low
free protein S, Table 2. Two of 8 men had Klinefelters
syndrome.
Of the 24 women taking ET before PE, 2 were diabetic,
1 had a previous history of thrombosis and 7 (29 %)
smoked, Table 1.
Of the 24 women, 18 had measures of coagulation,
and 16 (89 %) had ≥ 1 thrombophilia (Table 3). Four
women were V Leiden heterozygotes, 1 prothrombinin 8 men who using testosterone therapy before pulmonary
Factor VIII ACLA IgG Pro C PRO S Free S




223 47 49 43
14)
Table 3 Abnormal measures of thrombophilia and hypofibrinolysis in 24 women who used hormone replacement therapy on
estrogen-progestin oral contraceptives before pulmonary embolism (18 women had coagulation measures)
FactorV PTG Factor VIII FactorXI ACLAIgG ACLAIgM Lupus anticoagulant Pro S Free S Anti III


















adated cut point for IgG high: ≥ 23 GPL (before 10/31/12); ≥ 15 (after 11/1/12)
dated cut point for IgM high: ≥ 10 MPL (before 4/30/12); ≥ 13 (after 5/1/12)
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Factor XI, 2 were positive for the lupus anticoagulant, 3
had low protein S, 2 had low Free S, 3 had low anti-
thrombin III, and 3 had high ACLA, Table 3.
Cancer was associated with PE in 78 patients, 22 %
of the cohort (45 women [23 % of women], 33 men
[21 % of men], Table 1, Fig. 1). None of the cancer pa-
tients took either TT or ET, Table 1. Of the 33 men
and 45 women with PE and concurrent cancer (Fig. 1),
hospital based coagulation measures (Factor V Leiden,Table 4 Coagulation disorders in 24 cases (6 men [on testosterone]
therapy before PE, compared to 116 cases with PE but no hormone
cases (9 men, 8 women)
Factor V PTG MTHFR
Abnormal range TC,TT TC,TT TT
Hormone Cases
(n = 24,6 men on TT,
18 women on ET)
4/24 (17 %) 2/24 (8 %) 1/24 (4 %)
PE_no hormone, no Cancer
(n = 116, 62 men, 54 women)
15/105 (14 %) 7/71
(10 %)
Cancer (n = 17,9 men, 8
women)
0/15 (0 %)
**p < .025, comparing with Hormone cases by Fisher’s test
adated cut point for Homocysteine high: ≥ 15 (11/15/08-12/2/14); ≥10.4 (after 12/3/
bdated cut point for IgG high: ≥ 23 GPL (before 10/31/12); ≥ 15 (after 11/1/12)
cdated cut point for IgM high: ≥ 10 MPL (before 4/30/12); ≥ 13 (after 5/1/12)homocysteine, lupus anticoagulant, anticardiolipin anti-
body IgG and IgM, proteins C, S, and antithrombin III)
were obtained in 17 (9 men, 8 women, Tables 4 and 5).
Thrombophilia was rare in the 17 cancer patients with PE,
with exception of homocysteine, which was high in 40 %
of cancer patients, marginally more common than in the
24 hormone users (13 %, p = .063), Tables 4 and 5.
Of the 237 patients hospitalized with PE, free of cancer
and free of TT or ET supplementation, 116 had throm-
bophilia measures, Tables 4 and 5. These 116 cases didand 18 women [on estrogen]) who had testosterone/hormone





ACLA IgG ACLA IgM
4G4G umol/l Positive Datedb Datedc
1/24 (4 %) 3/24 (13 %) 2/24 (8 %) 2/24 (8 %) 2/24 (8 %)
18/43
(42 %) **
17/68 (25 %) 1/61 (2 %) 5/58 (9 %)
6/15 (40 %) 1/17 (6 %) 0/15 (0 %) 1/17 (6 %)
14)
Table 5 Coagulation disorders in 24 cases (6 men [on testosterone] and 18 women [on estrogen]) who had testosterone/hormone
therapy before PE, compared to 116 cases with PE but no hormone, no cancer (62 men, 54 women), and compared to 17 cancer
cases (9 men, 8 women)
Factor VIII Factor XI Protein C Protein S Free S Antithrombin III
Abnormal range > 150 % > 150 % < 73 % < 63 % < 66 % < 80
Hormone Cases (n = 24,6 men on TT,18 women on ET) 3/24 (13 %) 1/23 (4 %) 2/24 (8 %) 5/24 (21 %) 4/24 (17 %) 3/24 (13 %)
PE_no hormone, no Cancer (n = 116, 62 men, 54 women) 27/90 (30 %)* 8/77 (10 %) 11/74 (15 %) 8/80 (10 %)
Cancer (n = 17,9 men, 8 women) 1/16 (6 %) 1/16 (6 %) 1/14 (7 %)
* p < .05, comparing with Hormone cases by Fisher’s test
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cept for high homocysteine (42 % vs 13 %, p < .025) and
low protein C (30 % vs 8 %, p < .05), Tables 4 and 5.
Discussion
Increased risk of VTE in women using combined oral
contraceptives has been known for at least 52 years
[26], and is well recognized for hormone replacement
therapy [27]. By comparison, the association of VTE in
men [1] and women [4, 6] using TT has only
recently been described, as of 2011 and 2013–2015
respectively [1–6, 8]. Previously, in 596 men hospital-
ized for DVT-PE, we reported that 7 (1.2 %) had
taken TT before and at time of their admission [3],
and all 5 men who had evaluation of thrombophilia-
hypofibrinolysis were found to have previously undiag-
nosed procoagulants. Separately, we studied 147 men
hospitalized for DVT-PE, finding 2 (1.4 %) with ante-
cedent TT use, both of whom had previously undiagnosed
thrombophilia [5].
In the current study, of 154 men hospitalized for PE,
8 (5 %) used TT, and of 193 women, 24 (12 %) used ET.
congruent with previous studies [26, 27]. Congruent
with our previous reports [3, 5], all of the men with PE
after TT in the current study were found to have
familial-acquired thrombophilia, as were 16/18 women
(89 %) with PE after ET. Thrombophilia in the 24 cases
using TT and ET was comparable to that in 116 cases
not using TT or ET. As in the current study, when TT
or ET are given to patients with previously undiagnosed
thrombophilia, thrombosis commonly occurs [8].
In the current study, thrombophilia was rare in pa-
tients whose PE was associated with cancer, in agree-
ment with the report by Fiaz et al. [28] who reported
that thrombophilia was more common among VTE pa-
tients without cancer than in those with cancer.
Health [9, 10] and cost [29–31] ramifications of a PE,
either unprovoked or after TT or ET are significant.
After PE, there is a high cost of hospitalization, re-
hospitalization, and post-PE care [29]. As summarized
by Reitsma [32], “…the one-year mortality is 20 % after a
first VTE. Of the surviving patients, 15–25 % will experi-
ence a recurrent episode of VTE in the three years afterthe first event. Primary and secondary prevention is key
to reducing death and disability from VTE.”
Selective coagulation screening based on prior VTE
history, if applied to our 347 patients hospitalized for
PE, had low sensitivity, and would have identified only
25 % of men with PE on TT, and only 4 % of women
with PE on estrogen-progestin oral contraceptives-HRT.
However, cost-effectiveness studies [33, 34] suggest that
selective coagulation screening based on prior VTE his-
tory is more cost-effective than universal screening.
Limitations of our study include its retrospective ob-
servational nature, and a limited sample size of patients
who took TT or ET and had coagulation screening. Our
study is further limited by not having coagulation data
on patients admitted with PE who died before coagula-
tion measures were obtained.
Conclusions
Of 154 men hospitalized for PE, 8 (5 %) used TT, and
of 193 women, 24 (12 %) used ET. Our data suggests
that PE is an important complication of TT in men and
ET in women, in part reflecting an interaction between
familial and acquired thrombophilia and exogenous
hormone use.
Our findings may have important clinical ramifica-
tions, because VTE risk is an important determinant
of the benefit risk ratio of both TT and ET. In
women, PE accounts for about one third of the inci-
dence of potentially fatal VTE events associated with
HRT [35], and HRT increases the risk of VTE by 2- to
3-fold [36].
Reitsma [32] has concluded that “…for primary pre-
vention of VTE, genetic testing is not likely to play a
role in the future.” However, as the cost of screening
for familial and acquired thrombophilias falls over time,
with the development of multilocus genetic risk scores
to improve classification, we believe that coagulation
studies before starting TT, ET, and oral contraceptive
therapy should be done as an approach to primary
prevention of VTE, including at least PCR studies of
the Factor V Leiden and Prothrombin gene muta-
tions, Factors VIII and XI, homocysteine, and the lupus
anticoagulant.
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